Gilead Sciences Prevails in HIV Drug Patent Suit Against CDC

The Centers for Disease Control and Prevention breached three agreements it had with Gilead Sciences Inc. by failing to promptly notify the company of HIV drug inventions derived from work using the company’s research, the Court of Federal Claims ruled in a previously sealed decision.

Gilead sued the government in April 2020 alleging that the CDC violated three material transfer agreements and two clinical trial agreements by secretly patenting HIV treatments using information shared during the company’s development of Truvada for PrEP. The agreements provided that Gilead give the CDC drug compounds for free in exchange for the agency’s agreement …